Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Senate Medical Errors Legislative Inititatives Follow IoM Report

This article was originally published in The Gray Sheet

Executive Summary

Catalyzed by a recent Institute of Medicine report on use error, a bipartisan group of senators has begun drafting preliminary language for legislation that would "make critical changes in the nation's major federal health care programs to dramatically reduce the risk of medical errors," staffers report.

You may also be interested in...



FDA Device Reviews Need Stronger Patient Safety Criteria - IoM Report

FDA's Center for Devices and Radiological Health should place greater emphasis on patient safety in actual use and real-life settings when approving medical devices, the Institute of Medicine concludes in a report on medical errors, "To Err is Human," released Nov. 30.

‘Clear’ Is In The Eye Of The Beholder, New York, CRN Argue In Age-Restricted Sales Litigation

CRN’s request for clarification, as it continues litigating complaint in US District Court for Southern New York, highlights what it contends is vague and overly general language in the legislation passed in October with a 22 April effective date.

Biogen Sees Improving Momentum In Slow Leqembi Launch

Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT012898

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel